GANX — Gain Therapeutics Share News
0.000.00%
Last trade - 00:00Gain Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Gain Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview
Gain Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Brief: Gain Therapeutics Reports First Quarter 2023 Financial Results
Gain Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Gain Therapeutics Appoints C. Evan Ballantyne As Chief Financial Officer
Brief: Gain Therapeutics Reports Full Year 2022 Financial Results And Business Update
Gain Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Gain Therapeutics Announces Grant Award By Eurostars With Innosuisse For Alpha-1 Antitrypsin Deficiency Research Program
Gain Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Gain Therapeutics Presents New Preclinical Data From Its Gaucher Disease Program
U.S. RESEARCH ROUNDUP-Coherent, Huntington Ingalls Industries, Spirit Aerosystems Holdings
Gain Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Gain Therapeutics Inc. Reports Third Quarter 2022 Financial Results, Business Update
Gain Therapeutics Inc expected to post a loss of 46 cents a share - Earnings Preview
Brief: Gain Therapeutics Promotes Matthias Alder To Chief Executive Officer
Brief: Gain Therapeutics Presents Preclinical Data Showing Potential Disease Modifying Benefits Of Novel Brain Penetrant Small Molecule Candidate GT-02287
Gain Therapeutics Inc reports results for the quarter ended in June - Earnings Summary